Conferencia de resultados del 3T 2026 de Mobia Medical (MOBI): los ingresos aumentan un 73%, eleva las previsiones
Los ingresos de Mobia Medical (MOBI) en el tercer trimestre de 2026 aumentaron un 73 % hasta los 15,6 millones de dólares, el margen bruto alcanzó el 83,2 % y se elevó la previsión de ingresos para todo el año.
Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.